Evidence map›Paper›PMID 41999549›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.

Vivek Kumar Dhiman, Stuti Srivastava, Manju Kumari, Devendra Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vivek Kumar DhimanCentre for Herbal Pharmacology and Environmental Sustainability, Chettinad Hospital, and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, 603103, India.
Stuti SrivastavaFaculty of Biosciences, Institute of Biosciences and Technology, Shri Ramswaroop Memorial University, Lucknow, Uttar Pradesh, India.
Manju KumariDepartment of Biochemistry, King George's Medical University, Shah Meena Road, Lucknow, Uttar Pradesh, 226001, India.
Devendra SinghFaculty of Biotechnology, Institute of Biosciences and Technology, Shri Ramswaroop Memorial University, Barabanki, Uttar Pradesh, 225003, India. devendrasingh.ibst@srmu.ac.in.ORCID http://orcid.org/0000-0002-9795-5641

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid biopsy is the analysis of tumour components in bodily fluids and is increasingly considered a complementary approach to conventional diagnostics. Although tissue biopsy is the gold standard in clinical diagnostics, this approach is invasive, spatially restricted, and often difficult to perform repeatedly. Liquid biopsy is a minimally invasive approach for molecular analysis of tumours using circulating tumour DNA, cells, and extracellular vesicles, including exosomes. Although significant progress in this field has been made, a comprehensive synthesis of the biological basis, analytical methods, and clinical utility of these circulating markers still seems fragmented, with considerable methodological heterogeneity hindering standardised clinical use. This, in turn, underscores the need to understand the appropriate approach to the clinical utility of liquid biopsy. This review article is a concise and comprehensive synthesis of important liquid biopsy markers, a review of detection methods and their utility in cancer management, and an examination of the methodological limitations of this approach, including sensitivity, standardisation, and interpretation. This review article consolidates current evidence and highlights the importance of liquid biopsy and its utility for disease monitoring and precision oncology-based therapeutic decisions.

Indexed as

Biomarkers, TumorNeoplasmsCirculating Tumor DNAHumansLiquid BiopsyNeoplastic Cells, CirculatingBiomarkers, TumorCirculating Tumor DNABiomarkerBody fluidsLiquid biopsyManagementMedicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.